Regulators And Drug Makers Debate PRIME, EAMS, Adaptive Pathways - And More
This article was originally published in SRA
Executive Summary
Scrip Regulatory Affairs editor Maureen Kenny was at a conference in London yesterday where drug regulators and industry discussed key initiatives to support innovation and optimize pathways and timely access to new medicines.